Kraig Biocraft Laboratories, Inc. is a leading-edge biotechnology company focused on the development and commercialization of spider silk-based fibers. The company utilizes recombinant DNA technology to genetically engineer silkworms capable of producing silks with the properties of spider silk, which are known for their superior strength, elasticity, and durability. These advanced materials have potential applications across various industries, including medical, military, and textile sectors.

Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the technical textile and specialty fiber industries in the United States. The company's products are used in military and police applications for ballistic protection; industrial applications, including critical cables and abrasion/impact resistant components; safety equipment; and composite materials for the aero-space industry. Its products are also used in various markets, such as medical textiles, geotextiles, defense and military textiles, safe and protective clothing, filtration textiles, composites with textile structure, and functional and sportive textiles, as well as textiles used in buildings and transportation. The company was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.

Kraig Biocraft Laboratories, Inc. (Trading Symbol: KBLB) is a fully reporting biotechnology company focused on the development and commercialization of spider silks. As a reporting company, our annual and quarterly reports to the SEC can be found on EDGAR and on this website. Our investments in genetic research are targeted for product development and innovative near-term solutions to meet the practical problems of our world.

Our genetic engineering research has succeeded in developing what many considered to be the holy grail of material science: A practical and cost-effective technology for producing recombinant spider silk based fibers on an industrial scale. We are moving rapidly to commercialize of our spider silk technology, which we believe will have a significant impact on the global textiles industry. At the same time we are continuing to work in cooperation with leading laboratories to create new stronger and more flexible spider silk based fibers with potentially broad applications for consumers and industry in the multi-billion dollar marketplace for textiles and performance polymers.

At Kraig, we are passionate about pioneering the research, development and commercialization of the next generation of high performance fibers based on genetic engineered spider silk. We are the world leader in our field of genetic research and product development.

msh id	COM:KRAIGLABS
symbol	-
name	Kraig Biocraft Laboratories, Inc.
homepage url	https://kraiglabs.com
country	US
sector	Technology
industry	Biotechnology
market	STOCKS
employee count	11
crunchbase url	https://www.crunchbase.com/organization/kraig-biocraft-laboratories
linkedin url	https://www.linkedin.com/company/kraig-biocraft-laboratories-inc-
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	1.17K
monthly webtraffic growth	-0.57
growth score 14	12.67
growth score 28	18.7
growth score 90	39.82
growth score 365	29.46

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:KRAIGLABS

Kraig Biocraft Laboratories, Inc.

Last Close

0.09

21/11 17:24

Market Cap

141.22M

Beta: -

Volume Today

208.50K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-